Top Broker Regulation Stories
Roche warns of counterfeit cancer drug
By Matthew PerroneThe maker of the best-selling cancer drug Avastin is warning doctors and patients about counterfeit vials of the product distributed in the United States.
Brokers, human resources manager and other benefits professionals were thrust into the regulatory environment with the passage of the Affordable Care Act in 2010. As health care reform continues to evolve in a post-ACA world, we provide updates on the legislative front, and analysis and advice regarding the current regulatory environment, along with insights into what's next.
The maker of the best-selling cancer drug Avastin is warning doctors and patients about counterfeit vials of the product distributed in the United States.